Safety of sacubitril/valsartan initiated during hospitalization: data from a non‐selected cohort
Abstract Aims Sacubitril/valsartan is safe when initiated during hospitalization in a clinical trial setting. Its safety in real‐life population is not stablished. We compared the initiation of sacubitril/valsartan during hospitalization in a non‐selected population, in the PIONEER‐HF trial, and in...
Main Authors: | Juan Carlos López‐Azor, Lourdes Vicent, María Jesús Valero‐Masa, Alberto Esteban‐Fernández, Manuel Gómez‐Bueno, Ángel Pérez, Pablo Díez‐Villanueva, Javier De‐Juan, Ángel Manuel‐Iniesta, Ramón Bover, Susana delPrado, Manuel Martínez‐Sellés |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2019-12-01
|
Series: | ESC Heart Failure |
Subjects: | |
Online Access: | https://doi.org/10.1002/ehf2.12527 |
Similar Items
-
Real-world application of sacubitril/valsartan in patients suffering from heart failure with reduced ejection fraction
by: LUO Xiaoyu, et al.
Published: (2020-11-01) -
The role of sacubitril/valsartan in the management of cardiac resynchronization therapy non‐responders: a retrospective analysis
by: Kyeong‐Hyeon Chun, et al.
Published: (2020-12-01) -
Effects of Sacubitril/Valsartan on Serum Lipids in Heart Failure With Preserved Ejection Fraction
by: Senthil Selvaraj, et al.
Published: (2021-09-01) -
Reverse remodelling by sacubitril/valsartan predicts the prognosis in heart failure with reduced ejection fraction
by: Mi‐Gil Moon, et al.
Published: (2021-06-01) -
Sacubitril/Valsartan Induces Global Cardiac Reverse Remodeling in Long-Lasting Heart Failure with Reduced Ejection Fraction: Standard and Advanced Echocardiographic Evidences
by: Matteo Castrichini, et al.
Published: (2020-03-01)